Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer.

Hu J, Lai C, Xiao Y, Yan Z, Tan Y, Wang J, Qiu J, Li K, Yu H, Chen X, Han J, Cai X, Luo T, Deng C, Na R, He W, Xu K, Liu C

Open source

DOI: 10.1038/s41388-026-03946-y
Published: 2026 Oct
Container: Oncogene
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41388-026-03946-y,
  title = {Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer.},
  author = {Hu J and Lai C and Xiao Y and Yan Z and Tan Y and Wang J and Qiu J and Li K and Yu H and Chen X and Han J and Cai X and Luo T and Deng C and Na R and He W and Xu K and Liu C},
  year = {2026},
  journal = {Oncogene},
  doi = {10.1038/s41388-026-03946-y},
  url = {https://doi.org/10.1038/s41388-026-03946-y}
}

RIS

TY  - JOUR
TI  - Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer.
AU  - Hu J
AU  - Lai C
AU  - Xiao Y
AU  - Yan Z
AU  - Tan Y
AU  - Wang J
AU  - Qiu J
AU  - Li K
AU  - Yu H
AU  - Chen X
AU  - Han J
AU  - Cai X
AU  - Luo T
AU  - Deng C
AU  - Na R
AU  - He W
AU  - Xu K
AU  - Liu C
PY  - 2026
JO  - Oncogene
DO  - 10.1038/s41388-026-03946-y
UR  - https://doi.org/10.1038/s41388-026-03946-y
ER  -

APA

J, H., C, L., Y, X., Z, Y., Y, T., J, W., J, Q., K, L., H, Y., X, C., J, H., X, C., T, L., C, D., R, N., W, H., K, X., & C, L. (2026). Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer.. Oncogene. https://doi.org/10.1038/s41388-026-03946-y

Source records

pubmed · retrieved 2026-09-26T07:43:20.008Z